Innovations in Oral Therapies for Inflammatory Bowel Disease

OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis

(2019) Stefan Schreiber et al.   Journal of Crohns & Colitis

P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial

(2019) B G Feagan et al.   Journal of Crohns & Colitis

Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study

(2019) Laurent Peyrin-Biroulet et al.   GASTROENTEROLOGY

1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis

(2019) Laurent Peyrin-Biroulet et al.   GASTROENTEROLOGY

Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study

(2018) Remo Panaccione et al.   GASTROENTEROLOGY

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn’s Disease

(2018) Parambir S. Dulai et al.   GASTROENTEROLOGY

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

(2018) Julián Panés et al.   GASTROENTEROLOGY

Nonadherence to Biologic Therapies in Inflammatory Bowel Disease

(2018) Brian J Wentworth et al.   INFLAMMATORY BOWEL DISEASES

Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis

(2018) Bin Wu et al.   INFLAMMATORY BOWEL DISEASES

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease

(2018) Amy Hemperly et al.   INFLAMMATORY BOWEL DISEASES

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

(2018) Kevin L Winthrop et al.   INFLAMMATORY BOWEL DISEASES

OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study

(2018) S Danese et al.   Journal of Crohns & Colitis

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

(2018) Bruce E Sands et al.   Journal of Crohns & Colitis

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

The current state of the art for biological therapies and new small molecules in inflammatory bowel disease

(2018) Sudarshan Paramsothy et al.   Mucosal Immunology

Targeting JAK-STAT signal transduction in IBD

(2018) Christoffer Soendergaard et al.   PHARMACOLOGY & THERAPEUTICS

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

(2018) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue

(2017) Marco Spadaccini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

(2017) Pieter Hindryckx et al.   Journal of Crohns & Colitis

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

(2017) Julian Panés et al.   Journal of Crohns & Colitis

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease

(2017) Yun Qiu et al.   JOURNAL OF GASTROENTEROLOGY

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Crohn's disease

(2017) Joana Torres et al.   LANCET

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Managing side effects of JAK inhibitors for myelofibrosis in clinical practice

(2017) Iram Saeed et al.   Expert Review of Hematology

Next generation of small molecules in inflammatory bowel disease

(2016) Pablo Olivera et al.   GUT

Short Bowel Syndrome and Intestinal Failure in Crohnʼs Disease

(2016) Berkeley N. Limketkai et al.   INFLAMMATORY BOWEL DISEASES

What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance

(2016) Ailsa L. Hart et al.   Journal of Crohns & Colitis

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort

(2016) Akbar K. Waljee et al.   PLoS One

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

(2015) Julián Panés et al.   BMC GASTROENTEROLOGY

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

(2015) Hunar Abdulrahim et al.   EXPERT OPINION ON PHARMACOTHERAPY

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis

(2015) Naoki Yoshimura et al.   GASTROENTEROLOGY

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

(2015) Reena Khanna et al.   LANCET

Association between tumour necrosis factor-  inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study

(2015) N. Nyboe Andersen et al.   BMJ-British Medical Journal

Association between tumour necrosis factor-  inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study

(2015) N. Nyboe Andersen et al.   BMJ-British Medical Journal

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects

(2014) J. Voss et al.   ANNALS OF THE RHEUMATIC DISEASES

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues

(2014) Chunyi Wang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Budesonide multi-matrix system formulation for treating ulcerative colitis

(2014) Cosimo Prantera et al.   EXPERT OPINION ON PHARMACOTHERAPY

On the Colonic Bacterial Metabolism of Azo-Bonded Prodrugsof 5-Aminosalicylic Acid

(2014) Tiago Sousa et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants

(2014) Graham A Heap et al.   NATURE GENETICS

Small Intestinal Bacterial Overgrowth and Orocecal Transit Time in Patients of Inflammatory Bowel Disease

(2013) S. V. Rana et al.   DIGESTIVE DISEASES AND SCIENCES

Practical Strategies for Enhancing Adherence to Treatment Regimen in Inflammatory Bowel Disease

(2013) Rachel N. Greenley et al.   INFLAMMATORY BOWEL DISEASES

Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice

(2013) Toshihiko Sugiura et al.   Journal of Crohns & Colitis

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

Best strategies for global HCV eradication

(2013) Liesl M. Hagan et al.   LIVER INTERNATIONAL

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis

(2012) Sara N Horst et al.   EXPERT OPINION ON PHARMACOTHERAPY

Fingolimod-associated macular edema: Incidence, detection, and management

(2012) N. Jain et al.   NEUROLOGY

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy

(2010) R. HAMEDANI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Importance of disrupted intestinal barrier in inflammatory bowel diseases

(2010) Saʼad Y. Salim et al.   INFLAMMATORY BOWEL DISEASES

Development and characterization of colon specific drug delivery system bearing 5-ASA and camylofine dihydrochloride for the treatment of ulcerative colitis

(2010) Rupal Dubey et al.   JOURNAL OF DRUG TARGETING

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Integrins

(2009) Malgorzata Barczyk et al.   CELL AND TISSUE RESEARCH

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors

(2009) Florian Mullershausen et al.   Nature Chemical Biology

A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology

(2008) V. C. IBEKWE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

(2008) P. D. R. HIGGINS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS